Science brief
Israeli Biotech and Clinical AI Redefine Preventative Medicine
Breakthroughs at Weizmann and Technion target cancer metastasis and heart failure years before symptoms appear.
Science
Weizmann researchers identified sildenafil as a powerful inhibitor of cancer metastasis — setting up a cheap, repurposable drug combination that could starve tumors of essential cholesterol.
BackgroundMetastasis is the primary cause of cancer-related mortality, occurring when tumor cells migrate and colonize other organs. Aggressive cancer cells rely heavily on cellular cholesterol to alter their physical structure and detach, making cholesterol transport a critical target for therapy.
- Sildenafil blocks the PDE5 enzyme, boosting a signaling molecule that binds to the transport protein responsible for moving cholesterol within cells, which starves the cancer cell.
- Analyzing medical records of 5 million Clalit Health Services members showed that cancer patients taking sildenafil had dramatically higher survival rates, adding real-world weight to the laboratory findings.
- Combining sildenafil with cheap, cholesterol-lowering statins offers a promising, low-cost therapeutic path to prevent metastatic progression, potentially bypassing expensive drug-development cycles.
Science
The Technion-Leumit AI model predicts heart failure 5 years early — proving that cheap, continuous heart data can shift cardiology from reactive treatment to early prevention.
BackgroundHeart failure is a leading cause of hospitalization worldwide, but early cardiac changes are often completely imperceptible during standard clinical exams. Traditional diagnostic models rely on brief, 30-second electrocardiogram snapshots that frequently miss these subtle, long-term indicators of decline.
- The model was trained using 69,663 continuous 24-hour single-lead Holter electrocardiogram recordings spanning 20 years of patient history, creating an unusually robust dataset.
- DeepHHF achieved an Area Under the Curve (AUC) score of 0.80, significantly outperforming traditional short-segment models and human diagnostic accuracy to establish a new clinical benchmark.
- The platform identifies micro-arrhythmias and subtle cardiac anomalies invisible to clinicians, enabling early, preventative therapeutic interventions before symptoms worsen.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.